Yvonne McGrath
Direttore Tecnico/Scientifico/R&S presso ITEOS THERAPEUTICS, INC.
Patrimonio netto: 518 940 $ in data 31/05/2024
Profilo
Yvonne McGrath is currently the Chief Scientific Officer at iTeos Therapeutics, Inc. She previously worked as the Director & Chief Scientific Officer at Complix NV from 2014 to 2020.
Prior to that, she held the position of Head-Development at Immunocore Holdings Plc and Immunocore Ltd.
from 2010 to 2014.
Dr. McGrath completed her undergraduate degree at Queen's University Belfast and obtained a doctorate from Cardiff University School of Medicine.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
ITEOS THERAPEUTICS, INC.
0.09% | 07/03/2024 | 31 000 ( 0.09% ) | 518 940 $ | 31/05/2024 |
Posizioni attive di Yvonne McGrath
| Società | Posizione | Inizio |
|---|---|---|
| ITEOS THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/05/2020 |
Precedenti posizioni note di Yvonne McGrath
| Società | Posizione | Fine |
|---|---|---|
Complix NV
 Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Direttore Tecnico/Scientifico/R&S | 01/04/2020 |
| IMMUNOCORE HOLDINGS PLC | Corporate Officer/Principal | 01/04/2014 |
Immunocore Ltd.
 Immunocore Ltd. Pharmaceuticals: MajorHealth Technology Part of Immunocore Holdings Plc, Immunocore Ltd. is a British commercial-stage biotechnology company that develops and commercializes transformative medicines to address unmet needs in cancer, infection, and autoimmune disease. The company is based in Oxon, UK. The company has a robust pipeline of wholly owned and partnered programs to address a broad spectrum of disease indications, built on their proprietary soluble TCR bi-specific Immtac® platform. The company was founded in 2007, and the CEO is Bahija Jallal. | Corporate Officer/Principal | 01/04/2014 |
Formazione di Yvonne McGrath
| Queen’S University Belfast | Undergraduate Degree |
| Cardiff University School of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| IMMUNOCORE HOLDINGS PLC | Health Technology |
| ITEOS THERAPEUTICS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Complix NV
Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Health Technology |
Immunocore Ltd.
Immunocore Ltd. Pharmaceuticals: MajorHealth Technology Part of Immunocore Holdings Plc, Immunocore Ltd. is a British commercial-stage biotechnology company that develops and commercializes transformative medicines to address unmet needs in cancer, infection, and autoimmune disease. The company is based in Oxon, UK. The company has a robust pipeline of wholly owned and partnered programs to address a broad spectrum of disease indications, built on their proprietary soluble TCR bi-specific Immtac® platform. The company was founded in 2007, and the CEO is Bahija Jallal. | Health Technology |
- Borsa valori
- Insiders
- Yvonne McGrath
